



ISM Annual Meeting

Agenda of

Targeting Microbiota 2024

October 14 - 15, 2024 - Corinthia Palace, Malta

Day 1 - Monday, October 14, 2024

8h00 Materials Distribution & Welcome Coffee

8h50 Welcome Note of Targeting Microbiota 2024



Keynote Speech

9h00 – Phage Therapy: A New Era of "Old" Concept for "Microbiome" Health *Mzia Kutateladze, Eliava Institute of Bacteriophage, Georgia*

Session 1: Microbiota in Health & Disease: Advancements & Perspectives

Presentations duration: 20 minutes. Questions will be addressed during the panel discussion.

Chairpersons: Maria Cecilia Giron, Marvin Edeas



9h30 – Bacteriophages Redesigned – Tiny Killers and Detectives to Support Infectious Disease Therapy *Martin Loessner, ETH Zurich, Switzerland*



9h50 – **Mythbusting Our Microbiome Alan Walker,** University of Aberdeen, United Kingdom

10h10 Panel Discussion

10h20 Short Oral Presentations & Innovations (2 slots)

Presentations Duration: 7 minutes + 3 minutes for discussion

Addressing Risk Factors May Lead to Broader Use of Phage Therapeutics Tea Glonti, Queen Astrid Military Hospital, Belgium

Fecal Microbiota Analysis as a Predictive Tool for Cholestatic Diseases

Kihyun Ryu, Konyang University Hospital, South Korea

10h40 – 11h15 Coffee Break, Poster & Exhibition Session





11h15 – Gut Microbiome, Obesity & Diabetes: What's Next Hiroshi Ohno, RIKEN Center for Integrative Medical Sciences, Japan



11h35 – Gut Microbiome Signatures in Irritable Bowel Syndrome Simone Domenico Guglielmetti, Università degli Studi di Milano-Bicocca, Italy



11h55 – Gut Bacteria and Heart Healing: The Hidden Players in Post-Infarction Resilience *Patrick C. H. Hsieh, Academia Sinica, Tawian*

12h15 Panel Discussion

12h30 – 14h00 Lunch Break, Poster & Exhibition Session

Chairperson: Andreas Schwiertz



14h00 – Microbiota-Derived Extracellular Vesicles: Bridging Mother and Fetus *Justus Reunanen, University of Oulu, Finland*



14h20 – Deciphering the role of the Oral-Placental and Vaginal-Placental Microbiome Axes in Preterm Birth Souhaila Al Khodor, Sidra Medicine, Qatar



14h40 – Using Roseoflavin, a Natural Riboflavin Analogue, to Modify the Human Microbiota *Markus Egert, Furtwangen University, Germany*

15h00 Panel Discussion

15h10 – 15h50 Coffee Break, Poster & Exhibition Session

Chairpersons: Mzia Kutateladze, Markus Egert



15h50 – Culturing the Complexity of Intestinal Microbiota *in vitro* in Gut3Gel *Daniela Pacheco*, CTO and founder of Bac3Gel, Portugal



16h10 – From Microbiomes and (Meta)genomes to the Lab and Back - Identification, Production and Application of Bacteriocins

Christian Riedel, University of Ulm, Germany

16h30 Panel Discussion

16h40 Short Oral Presentations & Innovations (10 slots)

Presentations Duration: 7 minutes + 3 minutes for discussion

Assessment of Skinosal, a Synbiotic Supplement, in Reducing Allergy Symptoms in Ragweed-Sensitized Mice Olivier Raimond, Bellavie, Belgium

Resident Microbiota Promote the Acquisition and Pathogenesis of EBV and HIV

J. Victor Garcia Martinez, University of Alabama at Birmingham, USA

Resident Microbiota Regulates HIV Infection in the Central Nervous System

Angela Wahl, University of Alabama at Birmingham, USA

The Gut Microbiota Modulates Anastomotic Healing in Patients with Colorectal Cancer Undergoing Surgery Manuela M Santos, Université de Montréal, Canada

The Host Genotype Actively Shapes its Microbiome across Generations

Stefan Janssen, Justus Liebig University Giessen, Germany

Impact of Omega-3-Rich Fish Consumption on Faecal Short Chain Fatty Acid and Gut Microbiota Profiles Ainara Cano, AZTI Foundation, Spain

Interplay Between Host Genetics and Gut Microbiome Composition in the Japanese Population David Ortega Reyes, RIKEN, Japan

Air Pollution, Nasal Microbiota, and Bronchiolitis: Understanding their Interplay through a Multilevel Approach Luca Ferrari, University of Milan, Italy

A Novel *in vitro* Approach to Identify Microbial and Cellular Signatures of Short Bowel Syndrome (SBS) *Ludovica Marinelli, Ghent University, Belgium*

Exploring Connections between the Autonomic Nervous System, Microbiota-Gut-Brain Axis and Respiratory System: A Scoping Review

Karina Noelia Otero, Arturo Jauretche National University, Argentina

18h10 – 18h45 Questions & Discussion with all Speakers

Maria Cecilia Giron, Marvin Edeas, Mzia Kutateladze, Martin Loessner, Alan Walker, Hiroshi Ohno, Simone Domenico Guglielmetti,
Patrick C. H. Hsieh, Justus Reunanen, Markus Egert, Daniela Pacheco, Christian Riedel, Carmelo Scarpignato,
Koen Venema, Andreas Schwiertz, Rochellys Diaz Heijtz, José Manuel Fernández-Real, Ellen Blaak,
Pascale Vonaesch, Bina Joe and Cristian O'Flaherty

All questions will be designed to focus on the most significant and impactful issues.

18h50 End of Congress Day 1

20h30 Meet the Speakers Dinner (Reserved for ticket holders only)

Day 2 - Tuesday, October 15, 2024

8h25 Registration & Welcoming of Attendees

8h25 Opening of Day 2



Keynote Speech

8h30 – The Mystery of the Microbiome Genome: The Potential of 2 to 20 Million Microbial Genes to Transform Our Health

Marvin Edeas, Institut Cochin, INSERM U1016, Université de Paris, France

Session 2: Microbiome Medicine: Major Advances Towards Clinical Applications

Presentations length: 20 minutes. Questions will be addressed during the panel discussion.

Chairpersons: Bina Joe, José Manuel Fernández-Real



9h00 - Drug Effects of Gut Microbiota in Humans: Clinical Consequences

Carmelo Scarpignato, Chinese University of Hong Kong, China



9h20 - Targeting the Microbiota by Medical Professionals: Where are We Now?

Koen Venema, Maastricht University, Netherlands



9h45 – Probiotics & Health: How to Select the Right Strain?

Andreas Schwiertz, Institute of Microecology, Germany

10h05 Panel Discussion

10h20 Short Oral Presentations & Innovations (2 slots)

Presentations Duration: 7 minutes + 3 minutes for discussion

Gut3Gel: Innovative in vitro Platform for Evaluating Microbiome-Modulating Molecules

Victoria Navas, Bac3Gel, Portugal

Investigating whether Postbiotic-Rich Sourdough Bread Has the Potential to Confer Similar Health

Benefits to Consumers with Different Gut Microbiota Profiles

Emma Scott, UGent, Belgium

10h40 – 11h10 Coffee Break, Poster & Networking Session



11h10 – Gut Microbiota in Early Life: Impact on Neurodevelopmental Outcomes Rochellys Diaz Heijtz, Karolinska Institutet, Sweden



11h30 – Gut Brain Axis & Depression: Startegic Role of Dietary Proline Exposed

José Manuel Fernández-Real, Institut d'Investigació Biomèdica de Girona, University of Girona, Spain



11h50 – Does the Microbiome Control Cravings and Addictive Behavior of their Host: A New Prospective and Hope for Treating Addiction

Steven R. Gundry, The Centers for Restorative Medicine, USA

12h10 Panel Discussion

12h20 Short Oral Presentations & Innovations (2 slots)

Presentations Duration: 7 minutes + 3 minutes for discussion

Gene-Environment Interactions Relevant to Autism and Immune Impairment Cause Gut Microbial Dysbiosis in a Mouse Model of Colitis

Elisa Hill-Yardin, Royal Melbourne Institute of Technology, Australia

In silico Assessment of Diet's Effect on Gut Microbiota Interactions with Autism Spectrum Disorder Symptoms Using Machine Learning Derived Predictors

Juan Manuel Olaguez-Gonzalez, Tecnologico de Monterrey, Mexico

12h40 – 13h40 Lunch Break, Networking, & Poster Session

Chairpersons: Pascale Vonaesch, Hiroshi Ohno



13h40 – Microbial Phenotypes in Obesity: Implications for Precision Nutrition *Ellen Blaak, Maastricht University, Netherlands*



14h00 – Targeting Small Intestinal Microbiota: Impact on Metabolism

Pascale Vonaesch, Department of Fundamental Microbiology, University of Lausanne, Switzerland



14h20 – Prospects for Leveraging the Microbiota as Medicine for Hypertension *Bina Joe, University of Toledo, USA*



14h40 – Male Fertility and Gut Microbiota: Current Knowledge and Future Directions Cristian O'Flaherty, McGill University, Canada

15h00 Panel Discussion

15h15 Short Oral Presentations & Innovations

Presentations Duration: 7 minutes + 3 minutes for discussion

Radio-Chemotherapy Treatment Exacerbates Intestinal Dysbiosis in Cervical Cancer Patients from Western Mexico: Pioneering Study Characterizing Microbiota and NK Cell Exhaustion

Ksenia Klimov-Kravtchenko, Universidad de Guadalajara, Mexico

Optimizing Gut-on-a-Chip Technology with Probiotics to Decrease the Gap between Preclinical and Clinical Data Mari Lilith Lund, Novonesis, Human Health Biosolutions, Denmark

Uncovering the Potential of Nutritional Interventions to Rebuild Gut Health Post-Antibiotics

Azadeh Safarchi, MOSH-Future Science Platform, CSIRO, Australia

In vivo Synergistic Effects of *Lacticaseibacillus paracasei* 11w and Galactooligosaccharide on Psychobiotic and Antidiabetic Efficacy in Female Mice

Ashwinipriyadarshini Megur, Vilnius University, Lithuania

The Known Unknowns - The Mystery of Extracellular Vesicles of *Bifidobacterium* in Allergy Development Sabina Gorska, Polish Academy of Sciences, Poland

Microbial and Metabolic Shape of Remission and Exacerbation in Ulcerative Colitis Patients

Oliwia Zakerska-Banaszak, Institute of Human Genetics Polish Academy of Sciences, Poland

Why Settle for One? Combine 16S and mcrA Sequencing

David Novak, Masaryk University, Czech Republic

Modeling Microbiomes as (Approximately) the Sum of their Parts

Anthony Duncan, Quadram Institute, United Kingdom

16h35 Targeting Microbiota 2024 Concluding Remarks, Best Short Oral & Best Poster Awards

By Maria Cecilia Giron, President of ISM Marvin Edeas. Chairmen of the ISM Scientific Board

16h50 Drinks, Coffee and Snacks: Getting Together Networking

End of Targeting Microbiota 2024

For more information, please visit: www.microbiota-site.com.